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Abstract
Background: Diagnosis of Periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) is currently
based on a set of criteria proposed in 1999 modified from Marshall’s criteria. Nevertheless no validated evidence
based set of classification criteria for PFAPA has been established so far. The aim of this study was to identify
candidate classification criteria PFAPA syndrome using international consensus formation through a Delphi
questionnaire survey.
Methods: A first open-ended questionnaire was sent to adult and pediatric clinicians/researchers, asking to identify the
variables thought most likely to be helpful and relevant for the diagnosis of PFAPA. In a second survey, respondents
were asked to select, from the list of variables coming from the first survey, the 10 features that they felt were most
important, and to rank them in descending order from most important to least important.
Results: The response rate to the first and second Delphi was respectively 109/124 (88%) and 141/162 (87%). The
number of participants that completed the first and second Delphi was 69/124 (56%) and 110/162 (68%). From
the first Delphi we obtained a list of 92 variables, of which 62 were selected in the second Delphi. Variables reaching
the top five position of the rank were regular periodicity, aphthous stomatitis, response to corticosteroids, cervical
adenitis, and well-being between flares.
Conclusion: Our process led to identification of features that were felt to be the most important as candidate
classification criteria for PFAPA by a large sample of international rheumatologists. The performance of these
items will be tested further in the next phase of the study, through analysis of real patient data.
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Background
Periodic fever, aphthous stomatitis, pharyngitis and cervical
adenitis (PFAPA) is a recurrent fever syndrome that was
first described in 1987 [1]. The syndrome is characterized
by episodes of fever lasting 3–6 days with a regular recur-
rence (every 3–8 weeks), associated with at least one add-
itional clinical feature among aphthous stomatitis, cervical
adenitis, and pharyngitis [2]. PFAPA is not a well-defined
disease and there are no specific confirmatory laboratory or
genetic tests, which differs from the hereditary periodic
fever (HPF) syndromes. Currently the diagnosis of PFAPA
is based on modified Marshall’s criteria [2], but the results
of a recent survey emphasize the poor adherence of most
physicians to these criteria in their clinical practice [3]. Des-
pite a good sensitivity it has been demonstrated that a sig-
nificant number of patients with monogenic periodic fevers
(familial mediterranean fever (FMF), Tumor Necrosis Fac-
tor (TNF) receptor-associated periodic syndrome (TRAPS),
and Mevalonate Kinase Deficiency (MKD)) also meet the
diagnostic criteria for PFAPA syndrome, highlighting the
poor specificity of the diagnostic criteria [4, 5].
At variance with diagnostic criteria that should reflect
the heterogeneity of a disease in order to identify as
many people with the condition as possible, with high
sensitivity, the main purpose of classification criteria is
to standardize clinical definitions to be used in clinical
and pathogenic studies. For classification criteria, very
high specificity is required, whereas for diagnostic cri-
teria both specificity and sensitivity need to be close to
100%, which is difficult to achieve [6].
We report herein the results of an international pro-
ject aimed to identify the most important variables for
the proper classification of PFAPA patients. This is the
first step of a process aimed to develop new classifica-
tion criteria for PFAPA, through consensus formation
technique and data validation in the large dataset of the
Eurofever Registry [7].
Methods
For the development of the classification criteria for
PFAPA we used a multistep approach. The first step
(Delphi) which attempted to identify the most important
variables for the proper classification of PFAPA is
described in this manuscript.
Delphi Technique [8, 9] is a well-known consensus
formation method derived from the social sciences which
involves the attainment of consensus among a large group
of people through a series of surveys. While the first survey
is typically open ended, the following surveys are conceived
based on the results of the prior ones. Multiple inter-
national electronic surveys have been conducted via the
secured web based system of the Paediatric Rheumatology
INternational Trials Organization [10, 11] (PRINTO).
The first Delphi questionnaire was sent by e-mail to
all centers belonging to the PRINTO network that en-
rolled at least one patient in the Eurofever registry [7].
The surveys involved both adult and pediatric clinicians/
researchers worldwide. Participants were asked to iden-
tify the variables thought most likely to be helpful and
relevant for the diagnosis of PFAPA in current clinical
practice and in research setting. In the first survey par-
ticipants were asked to report, in an open fashion, all
measures they thought to be relevant for PFAPA based
on their clinical or research expertise. The question was:
“Please list the variables (as many as you like) that you
are currently using in your everyday clinical practice or
you consider to be the most useful for the diagnosis of
PFAPA. Variables to be included can be of any type: i.e.
clinical features, laboratory tests, genetic analysis etc.”
From the first survey we obtained a list of clinical and
laboratory variables which were checked for redundancy
and categorized into 5 domains. For each category, the
variables were listed in in alphabetical order with no in-
dication about the frequency of response for each item.
Additionally the list was updated with other variables
derived from a literature search performed by FV, SF
and MG.
The second Delphi questionnaire, based on the result
of the first one, was sent to all participants from the first
survey. In addition 43 North American clinicians/re-
searchers working in the field of autoinflammation and
members of Pediatric Rheumatology Collaborative Study
Group (PRCSG) and Childhood Arthritis and Rheuma-
tology research Alliance (CARRA), were also involved.
Participants were first asked to choose, among the vari-
ables listed, the 10 they consider as the most important
for the classification of PFAPA. In a second step, they
were asked to rank the previously selected items by
assigning them a score from 10 to 1 where 10 was for
the most important item and 1 for the least important.
They could use each rank only once, even though they
considered some features were equally important. At the
end of the questionnaire, the participants could add any
feature missing from the list that they considered as
relevant. The question was: “Please choose, from the
above mentioned list of items, the 10 top variables for
the classification of PFAPA and rank them in order of
importance.”
At least two reminders e-mail were sent to all investi-
gators who had not replied to the first or second survey.
The sum of ranks, frequency of citation and medium
score for each variable were calculated.
Variables falling in the 3rd quartile, considering the
total score obtained will be included in the subsequent
phases of the development of classification criteria in
which the ability of different set of criteria to classify in-
dividual patients as having PFAPA will be assessed. The
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best sets of criteria identified will be discussed in a face-
to-face consensus conference.
Results
The first survey was sent to 124 participants coming
from 63 countries.
One hundred nine recipients responded (88%): 75
(70%) participants responded to be interested in the
survey, 69 (56%) completed and confirmed it, 34 (27%)
responded not to be interested, 15 (12%) did not reply
(Fig. 1).
We obtained a list of 92 variables (Additional file 1:
Table S1 and S2) subsequently classified into 5 mutually
exclusive categories: 11 for characteristics of fever
episodes, 41 for signs and symptoms, 12 for history, 30
for laboratory parameters, 4 for others tests. Criteria
from the literature review were included in the list [2].
The five most cited variables were periodic fever, cervical
adenitis, aphthous stomatitis, pharyngo-tonsillitis and
abdominal pain. The exclusions of inherited monogenic
periodic fever and the response to corticosteroids were
cited by 24 and 43% of participants respectively. Several
participants cited as important the absence of specific
clinical manifestations i.e. absence of serositis or absence
of diarrhea.
The second survey was sent to 162 physicians, 119
from PRINTO and 43 from CARRA/PRCSG.
The overall rate of response was 87% (141/162): 110
(68%) experts completed the survey 88 from Eurofever/
PRINTO network and 22 from CARRA/PRCSG, 31
(19%) responded not to be interested, 21 (13%) didn’t
respond (Fig. 2).
At the end of the second Delphi survey we obtained a
list of 62 variables. For each variable the total score
(given by the sum of the score attributed by the partici-
pants citing that variable) was calculated.
For the subsequent statistical analysis we selected the
first 17 variables falling in the 3rd quartile considering
the total score obtained. The ranking including frequen-
cies of selection and mean score is shown in Table 1.
The highest score of 436 was reached by “regular peri-
odicity” whereas the most selected clinical variable was
aphthous stomatitis chosen by 77 participants.
None of the participants added any variables to the list
proposed, suggesting that participants agreed that the
items coming from the first survey were exhaustive.
All cardinal clinical signs (aphthous stomatitis, cervical
adenitis and pharyngitis) were included in the third
quartile at the second, fourth and sixtieth rank respect-
ively. Regular periodicity reached the highest score,
highlighting the importance of regularity of episodes in
the diagnosis of PFAPA. Response to corticosteroids and
response to tonsillectomy were also present. Concerning
the duration of fever episodes two items reached the
same score: duration of 3–5 days and duration of
3–6 days.
Others variables with a high rank were raised acute phase
reactants during fever episodes and their normalization be-
tween episodes, wellbeing between episodes, normal growth
and development and improvement with age.
Other variables like gastrointestinal/musculoskeletal
symptoms, headache and positive family history were
cited, but didn’t reach a sufficient score to be include in
the 3rd quartile (Additional file 1: Table S1 and S2).
Notably, age at onset < 5 years, which is present in the
modified Marshall’s criteria reached the 22th rank only.
Discussion
This is the first Delphi survey for the identification of
candidate variables for a new set of classification criteria
for PFAPA. Using the Delphi technique process involv-
ing a large number of clinicians and researchers world-
wide dealing with this condition, we obtained a list of
variables ranked in order of importance considered as
important for the identification of PFAPA patients.
The good rate of response to the Delphi underlined
the interest that clinicians and researchers involved in
autoinflammation have in this area. Globally, the results
of the Delphi reflect the elements that clinicians take
into account to identify PFAPA patients.
Participants confirmed the importance of most of the
variables already included in the modified Marshall’s
diagnostic criteria such as regular periodicity, aphthous
stomatitis, cervical adenitis, pharyngitis and wellbeing
between flares and normal growth and development.
The variable “Age at onset < 5 years” reached the
22th rank, suggesting that currently this features is no
longer considered such important. This may be due to
Fig. 1 Participants to the first survey. Summarize the participation rate to
the first survey, specifying number of recipients that not replied, number
of recipients interested in the survey and number of recipients that filled
the survey
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the fact that in the last few years it has been observed
that PFAPA onset may occur after 5 years [12] and to
date several cases of adult onset PFAPA have been de-
scribed [13]. This finding was confirmed in a recent
study in which was demonstrated that most physicians
do not require an age at onset < 5 years for diagnosis of
PFAPA [3].
The exclusion of cyclic neutropenia is cited in the list
together with exclusion of immunodeficiency. Cyclic
neutropenia is an important differential diagnoses for
PFAPA, due to its strict periodicity. This condition
generally begins within the first year of life and is char-
acterized by a cyclic reduction (every 3 weeks) of the
neutrophil count causing febrile attacks due to infec-
tions. For this reason a careful evaluation of cell blood
count during the first day of fever attacks may be useful
in the differential diagnosis.
Items associated to the exclusion of confounding
infectious conditions, such as “Absence of response to
antibiotics”, “Negative throat swab”, “Absence of con-
comitant respiratory symptoms” were cited by the clini-
cians but reached the 21st, 25th and 27th rank only,
respectively. The fact that these three items reached a
low score may be due to the fact that for physicians
involved in management of PFAPA the exclusion of the
other causes of recurrent fever (mainly upper respira-
tory airways recurrent infections) is implicit when
they consider a diagnosis of PFAPA in the everyday
clinical practice.
Less typical manifestations such headache, gastrointes-
tinal or musculoskeletal symptoms were included by
some clinicians, but did not reach the third quartile
(Additional file 1: Table S1 and S2). It is known that,
even if these features might be occasionally presents in
PFAPA subjects [12], the presence of abdominal pain
and diarrhea, are much more associated with the prob-
ability to carry relevant mutations in MVK, TNFRSF1A
and MEFV genes associated with mevalonate kinase defi-
ciency, TRAPS and familial Mediterranean fever, respect-
ively [14]. Therefore, the absence of these symptoms
may strengthen the suspicion of PFAPA.
Fig. 2 Participants to the second survey. Summarize the participation rate to the second survey, specifying number of recipients that not replied,
number of recipients interested in the survey and number of recipients that filled the survey, divided between PRINTO and CARRA networks
Table 1 Variables rank limited to the 3rd quartile
Rank Variable Score Frequence Mean score
1 Regular periodicity 436 56 7.8
2 Aphtous stomatitis 431 77 5.6
3 Response to steroid 401 66 6.1
4 Cervical adenitis 368 72 5.1
5 Well-being between flares 299 57 5.2
6 Pharyngitis (exudative
or not)
288 47 6.1
7 Increase of acute phase
reactants and serum
amyloid A during fever
episodes
271 44 6.2
8 Normal growth/
development
236 51 4.6
9 Pharingotonsillitis 228 35 6.5
10 Periodic fever 3–5 days 202 24 8.4
11 Periodic fever 3–6 days 202 23 8.8
12 Self-limiting episodes 183 35 5.2
13 Response to tonsillectomy 182 33 5.5
14 Improvement with age 160 40 4.0
15 Exclusion cyclic
neutropenia/
immunodeficiency
150 34 4.4
16 Normalization of acute
phase reactants in well-
being
146 33 4.4
17 Recurrence every 3–6
weeks
145 21 6.9
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Both the elevation of acute phase reactants during fever
episodes and their normalization in the periods between
episodes were indicated by participants and reached the
third quartile. An increase of the inflammatory parameters
during episodes is a mandatory element to point out a
possible autoinflammatory periodic fever [15], but does
not help in the discrimination of PFAPA from other
monogenic periodic fevers in clinical practice. The same is
also valid for the normalization of inflammatory parame-
ters between fever episodes, even if in some conditions
(FMF, cryopyrin associated periodic syndromes) sub-
clinical systemic inflammation can be detected.
The lack of pathognomonic test for PFAPA (i.e genetic
test or metabolic analysis available for other monogenic
periodic fevers) might increase the relevance of the
response to therapy (corticosteroid on demand or tonsil-
lectomy) in this condition. Indeed, both response to
corticosteroids and tonsillectomy were included in the
third quartile of the scores. Response to corticosteroids
on demand in particular reached the third rank. This
element was not considered in the previous criteria but
reflect an important element adopted by clinicians in
routine clinical practice. However it should be noted
that the same good response to corticosteroid on
demand has been reported in some monogenic periodic
fevers, like MKD and TRAPS [16]. It is questionable
whether the response to tonsillectomy is a good element
to support the diagnosis of PFAPA, since response to
tonsillectomy is also found in non-PFAPA recurrent
tonsillitis. Moreover, it is critical to confirm the diagno-
sis before a surgical procedure that furthermore is not
always necessary in PFAPA patients.
The exclusion of other monogenic periodic fevers, mainly
MKD is a crucial step for the classification of PFAPA [4].
According to the clinicians involved a “Negative genetic test
for monogenic autoinflammatory diseases” resulted at the
18th rank, falling out the 3rd quartile. It is conceivable that,
especially in typical cases the genetic analysis of genes asso-
ciated to HPF is not mandatory for the proper classification
of a PFAPA patient. On the other hand, the identification
of some variants of unknown significance in genes respon-
sible for other inflammatory conditions (i.e R202Q or
E148Q for MEFV, Q703K for NLRP3 gene, P46L or R92Q
for TNFRSF1A gene) should not exclude the classification
of PFAPA in a patient with a typical clinical phenotype [12].
It seems therefore crucial to elaborate clinical classification
criteria able to discriminate PFAPA from other autoinflam-
matory periodic fever with an high sensitivity and specifi-
city. Along these lines it is important to highlight that
among the variables cited in the first Delphi, many partici-
pants indicated also the absence of some manifestations
rather typical for monogenic periodic fevers, such as sero-
sitis, arthritis, diarrhea, eye involvement (Additional file 1:
Table S1 and S2). This is an interesting finding that
underlined the fact that sometimes even the absence of
some symptoms may have a relevant place in the classifica-
tion of a given disease, as recently shown by the preliminary
evidence-based criteria for monogenic HPF developed from
the Eurofever registry [17].
A possible limitation of this study is that specialists
possibly involved in the management of PFAPA patients
(infectious diseases specialists or oto-rhino-laryngologists)
were not part of this process. Nonetheless, the notion that
recurrent inflammatory fever episodes characteristics of
PFAPA should be carefully distinguished from other pos-
sible causes of recurrent fever (infections, immunodefi-
ciency, neoplasms) is rather consolidated in the pediatric
community [18]. Since, the major limitation of the on-
going PFAPA criteria is related to their low accuracy in
differentiating this condition from monogenic periodic
fevers (MKD, TRAS and FMF) [4], our main goal was to
involve a large number of clinicians with expertise in the
identification of all inflammatory causes of periodic/recur-
rent fevers, in order to identify clinical variables that
would be able to distinguish PFAPA on clinical grounds,
without the need to perform a molecular tests.
Conclusions
In conclusion, this study represents the largest Delphi
survey among clinicians and researchers dealing with
PFAPA and other autoinflammatory periodic fevers. The
process allowed the identification of those features that
are considered by clinicians the most important as can-
didate variables to be included in a new set of evidence-
based classification criteria for PFAPA. The performance
of these items will be tested further in the next phase of
the study, through analysis of real patient data.
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